Skip to main content

Sachs Bruce I's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Apr 14, 2023

Accession no.
0001209191-23-024305
Filed
Apr 14, 2023
Trade date
Apr 12-13, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.96M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sachs Bruce ICIK 0001197036Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 12, 2023Common StockMOption exerciseAcquired+21,300$72.14+$1,536,58262,510Direct
Apr 12, 2023Common StockSSaleDisposed−2,917$325.65F2,F3−$949,921.0559,593Direct
Apr 12, 2023Common StockSSaleDisposed−10,357$326.46F2,F4−$3,381,146.2249,236Direct
Apr 12, 2023Common StockSSaleDisposed−8,026$327.48F2,F5−$2,628,354.4841,210Direct
Apr 13, 2023Common StockGGiftDisposed−1,210$0.00$040,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 12, 2023Common StockMOption exerciseDisposed−21,300$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 3 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)